FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 316:1295-1301 May 21, 1987 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We studied an 18-year-old woman with progressive hirsutism, secondary amenorrhea, and polycystic ovarian disease. Excess androstenedione was secreted by the ovaries, most likely because of a genetic deficiency of ovarian 17-ketosteroid reductase, the enzyme that converts androstenedione to testosterone. Markedly elevated basal plasma levels of androstenedione, estrone, and testosterone were regulated by gonadotropin but not by ACTH. The rate of androstenedione production in the patient's blood at base line and after administration of dexamethasone was very high (10.0 to 11.6 mg per day; value in control women with hirsutism, less than 4.1 mg per day), whereas her blood production of testosterone was 0.64 to 0.7 mg per day, similar to or higher than that in control women with hirsutism. The fractional blood conversion ratio of androstenedione to testosterone was normal (5.6 percent). Thus, 88 to 93 percent of the testosterone in the blood was derived from the peripheral conversion of androstenedione, and very little testosterone was secreted by the ovaries. These in vivo biochemical data suggest that the patient had a deficiency of ovarian 17-ketosteroid reductase activity but normal pubertal activity. The patient's two younger sisters with peripubertal symptoms of androgen excess also had elevated serum levels of androstenedione. We propose that the increased secretion of androstenedione in the three siblings in this family was probably due to a genetic deficiency of ovarian 17-ketosteroid reductase.

This article has been cited by other articles:

• Escobar-Morreale, H. F., Luque-Ramirez, M., San Millan, J. L. (2005). The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome. Endocr. Rev. 26: 251-282 [Abstract] [Full Text]  
• Mendonca, B. B., Arnhold, I. J. P., Bloise, W., Andersson, S., Russell, D. W., Wilson, J. D. (1999). 17{beta}-Hydroxysteroid Dehydrogenase 3 Deficiency in Women. J. Clin. Endocrinol. Metab. 84: 802-804 [Abstract] [Full Text]  
• Castro-Magana, M., Angulo, M., Uy, J. (1993). Male Hypogonadism with Gynecomastia Caused by Late-Onset Deficiency of Testicular 17-Ketosteroid Reductase. NEJM 328: 1297-1301 [Abstract] [Full Text]  
• Barnes, R., Rosenfield, R. L. (1989). The Polycystic Ovary Syndrome: Pathogenesis and Treatment. ANN INTERN MED 110: 386-399 [Abstract]